Mode
Text Size
Log in / Sign up
N/A N=16 Randomized Double-blind Treatment

Effect of Oxytocin on Stress in Marijuana Users

Marijuana Dependence

Enrolled (actual)
16
Serious AEs
0.0%
Results posted
Aug 2014
Primary outcome: Primary: Stress (as Measured by Cortisol) — 1.8; 2.1 nmol/L

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Oxytocin (Drug); Saline (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Medical University of South Carolina
Primary completion
Jul 2012

Outcome Measures

OutcomeResultp-value
PRIMARY
Stress (as Measured by Cortisol)
1.8; 2.1
PRIMARY
Stress (as Measured by Subjective Report)
2.4; 3.0
SECONDARY
Craving (as Measured by the Marijuana Craving Questionnaire)
41.1; 53.4

Summary

The purpose of this study is to evaluate how people who frequently use marijuana respond to a stressful task, and if a medication (oxytocin) affects this response.

Eligibility Criteria

Inclusion Criteria

  • Subjects must be able to provide informed consent and function at an intellectual level sufficient to allow accurate completion of all assessment instruments.
  • Subjects must meet DSM-IV criteria for current marijuana dependence (within the past three months). While individuals may also meet criteria for abuse of other substances, they must identify marijuana as their primary substance of abuse and must not meet criteria for dependence on any other substance (except nicotine) within the last 60 days.
  • Subjects must consent to remain abstinent from all drugs of abuse (except nicotine and marijuana) for a three-day period immediately prior to the CTRC admission. Subjects must abstain from marijuana for 24 hours prior to testing. By restricting marijuana use as proposed, subjects should not be under the acute effects of marijuana, and also may be experiencing mild withdrawal symptoms, the measurement of which is one of the outcome variables being tested.
  • Subjects must consent to random assignment.

Exclusion Criteria

  • Women who are pregnant, nursing or of childbearing potential and not practicing an effective means of birth control.
  • Subjects with evidence of or a history of significant hematological, endocrine, cardiovascular, pulmonary, renal, gastrointestinal, or neurological disease including diabetes, as these conditions may affect physiological/subjective responses.
  • Subjects with Addison's disease, Cushing's disease or other diseases of the adrenal cortex likely to affect hormonal/neuroendocrine status.
  • Subjects with a history of or current psychotic disorder or bipolar affective disorder as these may interfere with subjective measurements.
  • Subjects with current major depressive disorder or post-traumatic stress disorder as these disorders are associated with characteristic changes in stress response.
  • Subjects receiving synthetic glucocorticoid therapy, any exogenous steroid therapy, or treatment with other agents that interfere with hormonal measurements within one month of test session.
  • Subjects taking any psychotropic medications, including SRI's or other antidepressants, opiates or opiate antagonists because these may affect test response.
  • Subjects with any acute illness or fever. Individuals who otherwise meet study criteria will be rescheduled for evaluation for participation.
  • Subjects who are obese (³ 20% over ideal weight) as this may interfere with hormonal status.
  • Subjects who are unwilling or unable to maintain abstinence from alcohol and other drugs of abuse (except nicotine) for three days prior to the stress task procedure.
  • Subjects meeting DSM-IV criteria for substance dependence (other than nicotine or marijuana) within the past 60 days.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01335789). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search